CDK4 and breast carcinoma: MDA-MB-453 LAR-type breast cancer cells are highly sensitive to CDK4/6 inhibitors (Asghar et al. 2017), and enzalutamide enhances the efficacy of palbociclib in AR-positive/RB-proficient TNBC cells (Liu et al. 2017).